Cicor acquires two production sites from Valtronic, marking its entry into the US market
- Cicor acquires Valtronic's US sites, expanding market.
- Acquisition adds 220 employees, boosts revenue by CHF 20M.
- Doubling capacity in Morocco enhances production efficiency.
|
Cicor Technologies Ltd / Key word(s): Mergers & Acquisitions Ad hoc announcement pursuant to Art. 53 LR |
Bronschhofen, 28 October 2025 – The Cicor Group (SIX Swiss Exchange: CICN) has signed an agreement to acquire two production sites from the Western Switzerland electronics supplier Valtronic on 27 October 2025. This move will strengthen Cicor's medical technology business, secure a strategic location in the USA and enable a much-needed expansion of capacity in Morocco.
Valtronic has over 40 years of experience in the development, industrialisation and manufacture of innovative medical and diagnostic devices, including active implants. In addition to
its headquarters in Switzerland, Valtronic operates production facilities in Berrechid (Morocco) and Cleveland (OH, USA), which specialise in the production of medical technology products.
As a result of the transaction, the Cicor Group will grow by around 220 employees and generate additional revenue of at least CHF 20 million, which could roughly double thanks to important new customers in the US business. The transaction will not have a
significant impact on the Cicor Group’s balance sheet or the EBITDA margin.
Local production in the USA
The acquisition of Valtronic gives Cicor its first location in the US, a facility in a very good condition with a strong local management and with the capacity to handle orders well over CHF 40
million. This move meets the needs of Cicor customers to produce in the USA. Setting up its own factory in the USA would have involved considerably higher investment and start-up costs for Cicor.
The acquisition of the Cleveland site from Valtronic is therefore an attractive and quick solution from an economic perspective.

